Xiyang Yang

Xiyang Yang

Auto-generated profile, based on publicly available information

Xiyang Yang

Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China; Institute of Life Sciences, Chongqing Medical University, Chongqing, 400010, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
DLDingyi Lv
Dingyi Lv
MINGHAO LUOMINGHAO LUO
MINGHAO LUO
ZCZhe Cheng
Zhe Cheng
RWRuiyu Wang
Ruiyu Wang
XYXiyang Yang
Xiyang Yang
JYJianghong Yan
Jianghong Yan
Myocardial ischemia‐reperfusion injury (MIRI) is a phenomenon that reperfusion leads to irreversible damage to the myocardium and increases mortality in acute myocardial infarction (AMI) patients. There is no effective drug to treat MIRI. Tubeimoside I (TBM) is a triterpenoid saponin purified from Chinese traditional medicine tubeimu. In this study, 4 mg/kg TBM was given to mice intraperitoneally at 15 min after ischemia. And TBM treatment improved postischemic cardiac function, decreased infarct size, diminished lactate dehydrogenase release, ameliorated oxidative stress, and reduced apoptotic index. Notably, ischemia‐reperfusion induced a significant decrease in cardiac SIRT3 expression and activity, while TBM treatment upregulated SIRT3’s expression and activity. However, the cardioprotective effects of TBM were largely abolished by a SIRT3 inhibitor 3‐(1H‐1,2,3‐triazol‐4‐yl) pyridine (3‐TYP). This suggests that SIRT3 plays an essential role in TBM’s cardioprotective effects. In vitro, TBM also protected H9c2 cells against simulated ischemia/reperfusion (SIR) injury by attenuating oxidative stress and apoptosis, and siSIRT3 diminished its protective effects. Taken together, our results demonstrate for the first time that TBM protects against MIRI through SIRT3‐dependent regulation of oxidative stress and apoptosis. TBM might be a potential drug candidate for MIRI treatment.

1 March 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
XYXiyang Yang
Xiyang Yang
XLXingbing Li
Xingbing Li
MINGHAO LUOMINGHAO LUO
MINGHAO LUO
YGYongzheng Guo
Yongzheng Guo
CLChang Li
Chang Li
JYJianghong Yan
Jianghong Yan